Neuronetics
Company · Malvern, Pennsylvania, USA
Makes NeuroStar, one of the first FDA-cleared TMS systems for major depression.
In the news
IndustryFunding
Neuronetics prices $30 million stock offering to pay down debt
The NeuroStar TMS maker sold 18.75 million shares at $1.60, partly to meet a loan amendment it says would resolve its going-concern risk.
IndustryNeuromodulation
Neuronetics grows revenue 12.5% and has an accelerated TMS protocol under FDA review
Clinic revenue drove the third quarter, while NeuroStar system sales were nearly flat. A 510(k) for a condensed treatment schedule was filed in August.